Dr. Alexander Drilon of Memorial Sloan Kettering Cancer Center recently reported at AACR on a potential new cancer treatment, Entrectinib, a receptor tyrosine kinase (RTK) inhibitor developed to target tumors carrying NTRK1, NTRK2, NTRK3, [...]
If you have a mutation of any of the SDH subunits (a,b,c, or d), the next important question to ask is whether or not it is a germline mutation. (So far, data has indicated that 80% of SDH-deficient tumors are germline). The term "germline" means that the mutation is present in every cell of your body. Germline mutations are hereditary, and can be passed on to your children. For this reason, genetic testing and counseling could be informative for parents, siblings and other family members. If a family member tests positive for the mutation, this does not mean that they will get GIST.
Recently a number of companies have begun to develop therapeutic options that target some of the rarer mutations in GIST. As there are currently no approved treatments specifically for these patients, this [...]
A recent call to action from ASCO (American Society of Clinical Oncology) published in the Journal of Clinical Oncology recommends expanding clinical trials to include more older adults. Given that greater than 60% of cancers in [...]
The 6th issue of the GIST Cancer Journal, official journal of the LRG and the first academic journal devoted solely to GIST is now available
This year, the Life Raft Group joined the Clinical Trials Transformation Initiative (CTTI) to help make clinical trials more efficient and productive and to help accelerate new treatments. CTTI is a consortium that brings [...]
A recent report from the Institute of Medicine outlines the advantages of data sharing from clinical trials. The authors state that data sharing can lead to the discovery of new treatment modalities as well [...]
The conversations about improving clinical trials to better meet the needs of cancer patients continue, with two noteworthy arguments set forth recently. Both arguments address the need to rethink the design of clinical trials.
Clinical trials are a key step in the development and approval of new drugs to treat cancer and often a lifeline to patients seeking options when other treatments have failed.